revenu figur prior figur
improv pt
messag maintain buy rate follow recent upgrad link
report earn week beat top bottom line strong jakafi
sale royalti guidanc assum continu growth across portfolio
 expens guid essenti stay flat pipelin timelin remain
track consist guidanc januari rais pt driven
higher jakafi growth assumpt faster margin improv vs previou
earn consensu strong jakafi growth report
revenu includ mileston contract revenu came
higher consensu includ jakafi sale
consensu attribut yoy revenu growth increas growth
among new patient second half oper expens slightli
estim result report bottom line beat
ep vs guggenheim estim consensu estim
guidanc upper end street expect guid toward jakafi
revenu vs consensu repres
growth confirm expect major growth come
volum oppos anticip price action addit guid toward
oper expens non- drive
margin expans manag confirm jakafi guidanc includ current
approv indic mf pv well minim contribut agvhd
indic readi immedi launch pend fda approv anticip
pemigatinib nda submiss cholangiocarcinoma track
confirm second line cholangiocarcinoma trial fulli
recruit team current wait top-line data matur manag
remind investor took month max respons rate seen
initi dataset present last year esmo team reiter guidanc
pemigatinib nda readi submiss recal pemigatinib also
evalu bladder cancer studi current recruit continu
dose cohort snda expect submit per manag guidanc
furthermor announc friday plan initi pivot tumor-agnost
trial evalu pemigatinib fgf/fgfr driver activ later
top-line date topic ruxolitinib phase ii vitiligo studi read
manag confirm on-going random phase ii trial evalu topic
ruxolitinib vitiligo track read first half year data posit
plan initi pivot phase trial indic pivot
stage program topic ruxolitinib recent initi phase trial atop
dermat follow impress phase ii data present last year eadv
addit updat expect includ data evalu ruxolitinib
agvhd evalu ruxolitinib cgvhd evalu
itacitinib steroid-na agvhd
model updat reflect faster jakaifi growth margin improv increas
assumpt jakafi growth pv main sourc sale
growth sinc label extens downward adjust oper expens mainli due
slower assum growth expens
page analyst certif import disclosur
valu per share use probabl adjust free cash flow project jakafi iclusig
olumi itacitinib topic ruxolitinib use discount rate consist
commerci stage biotech compani coverag termin growth rate
decreas oper expens thu increas margin near long term valu
previous
 regulatori commerci setback
potenti emerg new competitor
lower product sale expect
risk intellectu properti risk manag execut
page analyst certif import disclosur
chang fair valu acquisition-rel conting
interest incom net
unreal gains-to-loss long-term invest
incom tax
balanc sheet statement flow
compani report guggenheim secur llc estim
page analyst certif import disclosur
